Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
OXS-1550
i
Other names:
OXS-1550, DT2219ARL, OXS 1550, GTB-1550, DT 2219ARL, DT-2219ARL, DT2219, IND100780, anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
GT Biopharma
Drug class:
CD22-targeted antibody-drug conjugate, CD19-targeted antibody-drug conjugate, Protein synthesis inhibitor
Related drugs:
‹
inotuzumab ozogamicin (29)
TRPH-222 (1)
ADCT-602 (0)
RG7593 (0)
loncastuximab tesirine-lpyl (7)
SGN-CD19B (5)
IKS03 (2)
ABBV-319 (0)
SAR3419 (0)
SGN-CD19A (0)
MT-5111 (4)
omacetaxine mepesuccinate (4)
moxetumomab pasudotox (2)
recombinant (2)
MT-0169 (1)
Imtox19/Imtox22 (0)
MT-3724 (0)
SVC112 (0)
oportuzumab monatox (0)
minocycline (0)
RSO-021 (0)
inotuzumab ozogamicin (29)
TRPH-222 (1)
ADCT-602 (0)
RG7593 (0)
loncastuximab tesirine-lpyl (7)
SGN-CD19B (5)
IKS03 (2)
ABBV-319 (0)
SAR3419 (0)
SGN-CD19A (0)
MT-5111 (4)
omacetaxine mepesuccinate (4)
moxetumomab pasudotox (2)
recombinant (2)
MT-0169 (1)
Imtox19/Imtox22 (0)
MT-3724 (0)
SVC112 (0)
oportuzumab monatox (0)
minocycline (0)
RSO-021 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.